Thank you for submitting your manuscript for consideration by the EMBO Journal. It has now been seen by two referees whose comments are shown below. We share the referees' interest in this manuscript, but also felt at the editorial level that the dataset could be developed realistically to allow more general as well as more mechanistically developed conclusions. I outline below key points raised by the referees. I apologize for the atypically slow reviewing process due to some delays at the referee and unfortunately also at the editorial level due to high submission volumes during the main conference and holiday season.
Both referees 1 and 2 place these findings into a more complex general context and emphasize that the DR4 mechanism is likely to be one of several others, and they also point out that the current dataset does not allow extrapolation to a broader biological relevance. This has to be made clear in the revised manuscript. For example, ref 1 notes 'Whether this mechanism is mutually exclusive of others ... and whether it will generalize to other systems or to the in vivo situation has not been explored ... . ' Specific points raised by referee 1: > It is not clear if increased tBid is due to effects on p53-dependent Bid production. It is not clear if Bid mRNA is regulated by p53 in the present system with possible cleavage of newly synthesized full-length Bid. > The results are limited to the HCT116 cell line. > The fact that DR5 is upregulated by both nutlin and 5-FU is not sufficient evidence that it is not involved in the p53-dependent caspase 8 activation... The authors did not compare DR4 and DR5 with respect to effects of knockdown on the p53-dependent 5-FU induced cell death. The authors have not examined the transcriptional and [the] potential for mRNA stabilization of DR5 as compared to DR4. > The mechanism of DR4 mRNA stabilization is unclear. We would like to invite you to address the first four points experimentally, while the last point should be developed as far as possible in the limited revision time allocated.
Referee 2 also requests experimental revision: > how is the stability of DR4 mRNA regulated and is this p53 dependent? What is p53 doing to promote DR4 mRNA stability, and why is this not apparent in Nutlin treated cells? > Does this occur in other cells, or affect other mRNAs? > Is PUMA required for the 5FU-induced apoptosis? > Why is NOXA not induced in a p53-dependent manner in these cells? > How does the described pathway respond to other p53-inducing stimuli? > Is the whole pathway conserved in other cells? > What happens in RKO cells in response to Nutlin treatment? Again, we would like to encourage development of molecular mechanistic insight as far as possible. The generalization beyond the HCT116 cell line and to other p53 inducing stimuli should also be attempted. The other issues are all experimentally tractable and should be addressed.
Thus, I would like to invite you to submit a revised version of the manuscript, addressing the comments of both reviewers by textural revision and additional experimentation as appropriate. I should add that it is EMBO Journal policy to allow only a single round of revision, and acceptance of your manuscript will therefore depend on the completeness of your responses in this revised version.
When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process, please visit our website: http://www.nature.com/emboj/about/process.html
We generally allow three months as standard revision time. As a matter of policy, competing manuscripts published during this period will not negatively impact on our assessment of the conceptual advance presented by your study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed. Should you foresee a problem in meeting this three-month deadline, please let us know in advance -if no competing work is published in the meantime, we can certainly extend the deadline if necessary.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Yours sincerely, Editor
The EMBO Journal
This is an interesting paper where the authors investigate the molecular basis of p53-dependent apoptosis versus growth arrest in cells exposed to different stimuli. They suggest the different cell fates occur despite p53-dependent induction of p21, 14-3-3sigma, Bax, and Puma and that the difference pushing cells towards apoptosis involves p53-dependent caspase 8 activation, Bid cleavage and translocation to the mitochondria to stimulate cytochrome c release. The authors make a good case with high quality evidence, strongly implicating a death receptor-mediated extrinsic cell death cross-talk to mitochondrial apoptosis. The work does extend our understanding of cell fate in response to chemotherapy with 5-FU and provides what appears to be a solid example for a mechanism or switch that explains a very basic difference in outcome based on stimulus to the same cells. As such I am enthusiastic about this paper and will make some remarks to point out some weaknesses as well as to provide some additional information and perspective regarding exactly what is novel about this work.
The results are limited to the HCT116 cell line. This cell line is known to require cross-talk between caspase 8 activation and mitochondrial release of cytochrome c in a death signal amplification loop that facilitates efficient cell death. The only known connection between the extrinsic and intrinsic cell death pathways is caspase 8-dependent Bid cleavage and the authors do show that Bid is required for the apoptotic response that involves caspase 8 activation following exposure to the proapoptotic 5-FU. The importance of Bid to chemosensitivity has been previously suggested (Sax et al., Nature Cell Biol, 2002) by demonstration of p53-dependent upregulation of Bid mRNA in several systems and by the resistance of Bid-null MEFs to 5-FU and adriamycin. It is interesting that the most robust prior demonstrations of p53-dependent Bid induction were performed at the mRNA level, given the authors' demonstration that it is tBid that primarily accumulates following 5-FU exposure. It is not clear if increased tBid is due to effects on p53-dependent Bid production or other effects. It is not clear if Bid mRNA is regulated by p53 in the present system with possible cleavage of newly synthesized full-length Bid leading to elevated tBid levels.
Prior studies have implicated TRAIL receptor DR5 in p53-dependent 5-FU induced cell death in HCT116 cells. So similar to what the authors have done with DR4 knockdown, it was shown in 2004 (Cancer Res. 64:6666-6672, 2004 ) that knockdown of DR5 reduces 5-FU induced cell death of HCT116 cells (and reduces tumor growth in vivo). In the mouse where there is one pro-apoptotic TRAIL receptor (a hybrid of DR4 and DR5) that is transcriptionally regulated by p53, the role of this pathway has been shown to at least partially contribute to p53-dependent DNA damage induced apoptosis in various tissues in vivo following exposure to ionizing radiation (Mol Cell Biol 25:2000 -2013 , 2005 . The role of DR5 was also demonstrated in the human HCT116 cells in response to another chemotherapeutic agent CPT11, and interestingly in such cells there was an apparent difference between Bax deficiency and Bak deficiency (PNAS 100:15095-15100, 2003) . Prior studies have shown that p21 upregulation occurs equally well in cells that undergo cell cycle arrest versus those that undergo apoptosis (Cancer Res. 54:1169 , 1994 . The issue of the relationship between DR4 and DR5 homo and hetero-oligomers with respect to DNA damage-induced cell death has not been well-studied. The fact that DR5 is upregulated by both nutlin and 5-FU is not sufficient evidence that it is not involved in the p53-dependent caspase 8 activation given prior work implicating DR5 through specific knockdown experiments in HCT116 cells. The authors did not compare DR4 and DR5 with respect to effects of knockdown on the p53-dependent 5-FU induced cell death. Thus it should be carefully discussed that while the evidence appears to implicate DR4, it does not exclude an important role for DR5 especially given prior evidence. It should also be noted that the p53-dependent regulation of DR4 has not been widely observed or correlated with cell death as it has been observed for DR5. In fact the prevailing view is that DR4 may be more relevant for TRAIL-induced cell death whereas DR5 may be more relevant to cell death when TRAIL is combined with agents that activate the p53 pathway leading to cell death or sensitization effects. The authors have not examined the transcriptional and potential for mRNA stabilization of DR5 as compared to DR4. As the authors state the mechanism of DR4 mRNA stabilization is completely unclear.
It is difficult to conclude in a general way that this death receptor signaling and not other proapoptotic mediators is the key difference between apoptosis and growth arrest responses if the experiments are performed in one cell line. There are certainly examples where differences in proapoptotic gene transcriptional induction does appear to correlate well with cell fate and there is certainly tissue-specificity in the p53-dependent transcriptional response in vivo (Mol Cell Biol 22:4280-4292, 2002 , Oncogene 20:4601-4612, 2001 , Cancer Res. 62:7316-7327, 2002 , Cell Cycle 10:2380 -2389 , 2011 . Interestingly in response to ionizing radiation, p53-dependent transcription in vivo leads to DR4/5 upregulation in tissues that undergo apoptosis but not in those that undergo growth arrest (Oncogene 20:4601-4612, 2001 , Cancer Res. 62:7316-7327, 2002 , Mol Cell Biol 25:2000 -2013 , 2005 . It is also important to recognize that cell fate is not entirely dependent on the p53 response but involves other elements of the cellular stress response including NFkB and Akt and that these pathways impact on mitochondrial cytochrome c release through described effects on the Bcl2 family and the balance of pro-apoptotic versus anti-apoptotic members. The mechanism described in this paper could be considered as yet another way that may determine cell fate in response to different stimuli that lead to the alternative outcomes of growth arrest versus apoptosis. Whether this mechanism is mutually exclusive of others that have been described and whether it will generalize to other systems or to the in vivo situation has not been explored and remains to be unraveled.
Referee #2
This study addresses the interesting question of how the response to p53 activation is controlled. It is well established that activation of p53 can result in a number of cell fates, including cell cycle arrest and apoptosis. As outlined by the authors in this paper, factors that affect the function of p53 as a transcription factor (leading to differential activation of p53 target genes under different circumstances) as well as p53-independent events may both play a role. The authors suggest here that they have identified a p53-dependent activity that promotes the stabilization of DR4 mRNA as another mechanism that can determine the induction of apoptosis.
1. The final part of the work is incomplete. Most pressingly, how is the stability of DR4 mRNA regulated and is this p53 dependent? Does this occur in other cells, or affect other mRNAs? What is p53 doing to promote DR4 mRNA stability, and why is this not apparent in Nutlin treated cells?
2. The authors suggest that activation of PUMA is not sufficient to induce apoptosis, although previous studies have shown that over-expression of PUMA in these cells can promote cell death. This seems to raise the possibility that the authors are also seeing a protective effect associated with p53 induction in the Nutlin treated cells. Is PUMA required for the 5FU-induced apoptosis?
3. Why is NOXA not induced in a p53-dependent manner in these cells?
4. Figure 2B should include p53 null cells -I assume the accumulation of tBID at the mitochondria is p53-dependent, but in light of the NOXA results this should be shown. Minor point, in page 11 the reference to Figure 5C (3rd paragraph) should be 5E. Point-by-point response to referee's comments. Manuscript EMBOJ-2011-78546
We thank both reviewers for their hard work, which be believe has produced a fair and constructive critique of our work. We are also grateful for their enthusiasm toward the results in this manuscript. We have taken their criticisms to heart and worked hard to produce what we believe is a muchimproved manuscript. We hope the reviewers will find the additional experiments and the text revisions satisfactory. Below is a point-by-point response to the critiques.
Reviewer #1:
With help from the Editor, we have condensed Reviewer's #1 critique to the following four key points:
It is not clear if increased tBid is due to effects on p53-dependent Bid production. It is not clear if
Bid mRNA is regulated by p53 in the present system with possible cleavage of newly synthesized full-length Bid.
In response to this comment, we have analyzed total BID levels by Western Blot and Q-RT-PCRs in p53 +/+ and p53 -/-cells (see Figure 2A , new panel in Figure 3B and Supplementary Figure S3 ).
These experiments show that BID expression at the total protein and mRNA levels is not induced upon p53 activation by Nutlin-3 or 5FU in HCT116 cells. However, BID cleavage upon 5FU treatment is p53-dependent ( Figure 3B ) and also caspase 8-dependent ( Figure 3E ). We also show that caspase 8 activation is p53-dependent ( Figure 3B ). Therefore, we conclude that increased tBID is not due to p53-dependent transactivation of the BID locus as demonstrated in other systems but rather to p53-dependent activation of caspase 8. The Discussion has been revised to acknowledge that in other paradigms BID has been shown to be a direct transcriptional target of p53.
The results are limited to the HCT116 cell line.
We thank both reviewers for the suggestion to test for the conservation of the novel pathway in another cell line. The revised paper contains new data demonstrating the importance of the DR4/FADD/Caspase 8/tBID axis in a cancer cell line of different origin (H460, non-small cell lung carcinoma) (see Figure 7 and Supplementary Figure S7 in the revised manuscript). We repeated all key Western Blots in H460 cells, which demonstrate that 5FU treatment, but not Nutlin-3, leads to increased DR4 expression, caspase 8 activation, BID cleavage and activation of executioner caspase 3. Furthermore, we established the four key stable shRNA knockdowns (DR4, FADD, caspase 8 and BID) in H460 cells and found that all four factors are required for full caspase activation and induction of apoptosis in response to 5FU. We also show that DR4 mRNA accumulates to greater levels in this cell line upon 5FU treatment as compared to Nutlin-3. In summary, the DR4/tBID axis is not exclusive to colorectal cancer cell lines and is found in cancer cell types of other origins.
The fact that DR5 is upregulated by both nutlin and 5-FU is not sufficient evidence that it is not involved in the p53-dependent caspase 8 activation. The authors did not compare DR4 and DR5 with respect to effects of knockdown on the p53-dependent 5-FU induced cell death. The authors have not examined the transcriptional and [the] potential for mRNA stabilization of DR5 as compared to DR4.
We thank the reviewer for this comment, which highlighted the need to integrate our findings on DR4 with what has been previously reported for DR5. We should clarify at this point that we never claimed that DR5 was not important for 5FU-induced apoptosis as has been previously shown in elegant work by the El-Deiry group. What we did conclude is that the choice between arrest and apoptosis was not likely due to differential induction of DR5, because DR5 is activated equally by both 5FU and Nutlin-3. This observation lead us to focus on DR4, which is activated by 5FU but not Nutlin-3, and to investigate the mechanisms underlying its differential activation. Nevertheless, in response to this comment we have now tested the impact of DR5 knockdown on 5FU-induced apoptosis in our systems. In complete agreement with published work, we found that DR5 knockdown causes a reduction in caspase 8 and caspase 3 activation upon 5FU treatment and that it also reduces 5FU-induced apoptosis (see new Supplementary Figure S6 ). Since these results are in agreement with previous published work by the El-Deiry group, we believe it should remain in the supplementary figure. Since DR5 is activated similarly by both drugs, we believe there is no need for further mechanistic studies on this well studied receptor. Finally, following this comment by the reviewer, we have modified the discussion extensively to make clear that we do not deny a contribution of DR5 to 5FU-induced apoptosis and to include more pertinent references integrating our new findings with previous work on DR5.
The mechanism of DR4 mRNA stabilization is unclear.
In response to this comment we have performed more experiments in this area. We show now that DR4 mRNA stabilization upon 5FU treatment is p53-independent and that it is not exclusive to the DR4 mRNA, as it is also observed for NOXA. However, this mRNA stabilization phenomena is not universal, as the mRNAs for other p53 target genes (e.g. MDM2) are not stabilized. A further characterization of the mechanism driving this mRNA-specific stabilization event lies beyond the scope of the current manuscript, which is already quite large, and will be investigated in future studies.
Finally, in response to the thoughtful comments provided by this reviewer, we have revised our Results and Discussion sections to place our new findings in the context of other work in the field. We thank the reviewer for the different citations, which are now discussed in the revised manuscript.
Reviewer #2

How is the stability of DR4 mRNA regulated and is this p53 dependent? What is p53 doing to promote DR4 mRNA stability, and why is this not apparent in Nutlin treated cells? Does this occur in other cells, or affect other mRNAs?
Please see response to Reviewer's #1, point #4 above. We should clarify here that we never claimed that DR4 mRNA stabilization was p53-dependent. In fact, the revised manuscript reports new data demonstrating that DR4 stabilization also occurs in p53 -/-cells treated with 5FU. Thus, this stabilization event is likely produced by the action of 5FU on parallel pathways. This illustrates how p53-independent events (i.e. DR4 mRNA stabilization) collaborate with p53-dependent events (i.e. transactivation of DR4, PUMA and DR5; translocation of BAX into the mitochondria) to switch the cellular response from cell cycle arrest into apoptosis. This is depicted in our model in Figure 8 . Finally, differential activation of DR4 is indeed observed in other cell types (please see response to Reviewer's #1, point 2, above) and also affects other mRNAs such as NOXA (please see response to Reviewer's #1, point 4, above and point # 3 below).
The authors suggest that activation of PUMA is not sufficient to induce apoptosis, although previous studies have shown that over-expression of PUMA in these cells can promote cell death. This seems to raise the possibility that the authors are also seeing a protective effect associated with p53 induction in the Nutlin treated cells. Is PUMA required for the 5FU-induced apoptosis?
We are grateful to Reviewer #2 for this comment, which highlights the need for a better explanation of our interesting results regarding the role of PUMA in p53-dependent apoptosis and the contextdependent configurations of the p53 network in different cell types and signaling scenarios. First of all, it has been amply established by others and ourselves that PUMA is indeed required for 5FU-induced apoptosis and that PUMA overexpression is sufficient to induce apoptosis in a variety of systems (Gomes & Espinosa, 2010; Nakano & Vousden, 2001; Yu et al, 2001) . However, what our present work clearly demonstrates is that physiological PUMA induction upon p53 activation by Nutlin-3 is clearly not sufficient to induce apoptosis. Thus, overexpression experiments should be interpreted carefully. The reviewer is correct in hypothesizing that HCT116 cells are protected from the effects of endogenous PUMA by the action of survival factors, some of which may be induced by Nutlin-3 itself. Indeed, in a previous publication we showed that HCT116 cells are protected by the killing effects of Nutlin-3 by the fact that p53 induces p21, 14-3-3s and miR-34a, three factors mediating cell cycle arrest downstream of p53 and thus partially protecting from apoptosis (Paris et al, 2008) . In fact, we found that HCT116 p21 -/-14-3-3s -/-cells where miR-34a is inactivated with 'antagomirs' fail to properly arrest and show signs of apoptosis upon prolonged Nutlin-3 treatment. Additionally, we reported that cell lines where Nutlin-3 induces rapid apoptosis show impaired induction of one or more of these cell cycle inhibitors. In the extreme case of the BV173 cell line, which undergoes rapid apoptosis within 24 hours of Nutlin-3 treatment, we found that the p21 mRNA is rapidly degraded and the p21 protein never expressed, that the 14-3-3s promoter is silenced by DNA methylation and that the primary transcript for miR-34a is not processed into the mature microRNA. In addition to the effect of these cell cycle inhibitors, HCT116 cells are also protected from the killing effects of PUMA by members of the BCL2 family. In fact, we and others have found that knockdown of BCL2 sensitizes cells to Nutlin-3-induced apoptosis and that the BH3 mimetic ABT-737 synergizes with Nutlin-3 to induce cell death (Sullivan and Espinosa, submitted; (Wade et al, 2008) ). The Discussion of the revised manuscript has been expanded to address this comment by Reviewer #2 along the lines described above.
Why is NOXA not induced in a p53-dependent manner in these cells?
We thank Reviewer #2 for this comment, which led us to another interesting result. First of all, we should point out that we were equally surprised by this observation, as NOXA is usually depicted as a canonical p53 target gene during genotoxic stress. However, we were pleased to find that others have previously observed that NOXA induction in response to 5FU is p53-independent. In their 2001 paper reporting the discovery of PUMA, the Vogelstein group also observed that while PUMA induction upon 5FU and adriamycin is p53-dependent, NOXA induction is not (see Figure 1C in (Yu et al, 2001) ). In response to this reviewer comment, we decided to examine NOXA mRNA stability upon 5FU treatment and found that indeed NOXA mRNA is clearly stabilized in a p53-independent manner upon 5FU treatment only, as observed for the DR4 mRNA (new Figure 6) . In fact, if anything, loss of p53 increases this stabilization effect, which correlates with the fact the NOXA mRNA is induced to greater extents in p53-/-cells (see Q-RT-PCR in Supplementary Figure S2 ). Thus, 5FU treatment leads to stabilization of diverse apoptotic mRNAs. Although elevated NOXA expression does not significantly contribute to apoptosis in this scenario (Figure 2) , we have nonetheless included the mRNA stabilization data in the revised manuscript ( Figure 6 ). In future studies beyond the scope of this manuscript we will investigate how DR4 and NOXA mRNAs are stabilized upon 5FU-treatment.
How does the described pathway respond to other p53-inducing stimuli?
In response to this comment we tested various p53-inducing stimuli in our system. In the new Supplementary Figure S8 , we show a side-by-side comparison of the effects of Nutlin-3, 5FU, doxorubicin, camptothecin, etoposide and UVC. Although, all of these drugs lead to p53 activation, we and others have previously shown that only 5FU and UVC lead to rapid apoptosis in this cell line (Bunz et al, 1999; Donner et al, 2007; Gomes & Espinosa, 2010) . In contrast, the topoisomerase inhibitors lead to cell cycle arrest mostly in G2/M and to a lesser extent in G1 (Bunz et al, 1998; Bunz et al, 1999; Gomes et al, 2006) . Accordingly, only 5FU and UVC lead to activation of caspase 8 (Supplementary Figure S8) . In order to define if 5FU and UVC induce apoptosis by identical mechanisms, we tested the impact of shRNAs against BID, caspase 8, DR4 and FADD as well as p53 knock-out on UVC-induced apoptosis. Expectedly, p53 knock-out significantly reduced caspase 3 activation upon UVC. Interestingly, we found that whereas knockdown of BID, caspase 8 and FADD impaired activation of caspase 3 after UVC, the effects of DR4 knockdown were negligible. Thus, we conclude that both 5FU and UVC require a functional FADD/caspase 8/BID axis to induce apoptosis, but that only 5FU requires DR4, suggesting that UVC utilizes an alternative pathway for caspase 8 activation.
Is the whole pathway conserved in other cells?
The answer is YES! Please see response to Reviewer #1, point # 2. Thank you for resubmitting your manuscript for consideration by the EMBO Journal. It has now been seen again by both referees -both are entirely satisfied with this revision. We have noticed a couple of minor issues about the data that should be rectified:
> In all panels describing statistical tests the number of independent repeats of an experiments is described as three or more. Please indicate the actual n -if it varies between measurements, we would recommend adding n above each bar. > The Cox4 panels in fig 1C and 1B are identical. This is essentially a similar experiment and it might in fact be the same experiment. If that is so, this should be clearly stated in the legend noting this is the same panel to avoid confusion.
You may have noticed that we now encourage presentation of source data for the key figure panels; this includes uncropped versions of key blots. We recommend that uncropped blots are labelled to that the related figure panels can be clearly identified. Ideally MW markers should also be included and marked. The cropped actual figure panel can be usefully marked up as a red stippled box. we will add these panels in the figures as 'source data' for the interested expert reader and we would encourage you add this information at least for selected key panels.
Thank you for the opportunity to consider your work for publication. I look forward to publish this work as soon as possible. Please resubmit via the link below and ensure that we received all the relevant forms to avoid deleays.
Yours sincerely,
Editor
------------------------------------------------REFEREE COMMENTS
Referee #1 (Remarks to the Author):
My concerns have been addressed.
Referee #2 (Remarks to the Author):
The authors have answered my comments.
2nd Revision -authors' response 01 December 2011
We are very grateful to the reviewers and editors for what we believe has been a very constructive critique of our work. The final version of the manuscript and figures have been modified as suggested by the editors to include the following changes:
• The actual 'n' for each statistical test performed has been added above the bar next to the respective P value. Accordingly, 'of at least three independent experiments' has been removed from the text of all main and supplementary figure legends.
• We have clarified in the text of the legend for Figure 2B that the COX4 Western blot is the same exact blot as shown in Figure 1C because the data are from the same experiment.
